Intraoperative evaluation of tumor margins using a TROP2 near-infrared imaging probe to enable human breast-conserving surgery.
Weiling Chen, Yongqu Zhang, Lixin Zhang...
https://pubmed.ncbi.nlm.nih.gov/39413161/Actively Recruiting
Led by Yunnan Cancer Hospital · Updated on 2026-08-31
40
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are investigating a new method to improve the diagnosis of oral squamous cell carcinoma OSCC, a type of oral cancer, by using a special molecular imaging probe called TTP-ICG. This probe targets a protein called TROP2, which is often found in high amounts on cancer cells. The study aims to develop a precise, less invasive, and cost-effective way to detect oral cancer early, since current biopsy methods can be invasive and sometimes give incomplete results due to the complex nature of the lesions. During the study, clinical specimens removed during surgery will be soaked in solutions of the TTP-ICG probe at different concentrations and incubation times. After soaking and rinsing, the specimens will be imaged with a near-infrared fluorescence system to capture detailed images. The team will then analyze the images alongside traditional pathological tests to understand how well the probe highlights cancerous tissue. The researchers are also exploring using a mouthwash-based delivery of the probe in the future. Participants will undergo surgical treatment as decided by their doctors, and their removed tissue will be studied using the TTP-ICG probe. The study involves collecting imaging data as well as performing standard pathology analyses including staining and immunohistochemistry. Researchers will measure the fluorescence intensity in cancerous and non-cancerous tissues to evaluate the probes accuracy. The study is expected to last until early 2027, with participant ages ranging from 18 to 75 years.
CONDITIONS
Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer
Y
Yixin Chen, postgraduate
J
Jingwen Bai,Doctor, doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Yunnan Cancer Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to surgery day and immediate post-surgery period
Participants undergo surgical treatment based on clinical diagnosis. Removed tissue samples are soaked in the TTP-ICG probe solution, rinsed, dried, and then imaged using a near-infrared fluorescence system. Pathological tests are performed and the imaging results are analyzed.
Surgical and imaging visits as scheduled
Duration - Up to 1 year
Researchers analyze fluorescence imaging data alongside pathology results to evaluate diagnostic accuracy. Participants continue their usual medical care with their doctors.
Follow-up visits as needed
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Weiling Chen, Yongqu Zhang, Lixin Zhang...
https://pubmed.ncbi.nlm.nih.gov/39413161/Yunnan Cancer Hospital
Lead Sponsor